AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...
The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.
AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...
AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous, ...
8d
AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first ...
GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
StockNews.com lowered shares of Innoviva (NASDAQ:INVA – Free Report) from a buy rating to a hold rating in a report published on Thursday. Innoviva Price Performance Shares of INVA opened at $18.08 on ...
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...
Venatorx meanwhile is developing a pipeline of novel combinations of beta-lactam antimicrobials and beta-lactamase inhibitors – drugs used alongside the antibiotics to prevent resistance – for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback